Welcome to our dedicated page for ProQR Therapeutics N.V. SEC filings (Ticker: PRQR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ProQR Therapeutics N.V.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ProQR Therapeutics N.V.'s regulatory disclosures and financial reporting.
ProQR Therapeutics N.V. reports that Chief Executive Officer Daniel Anton de Boer purchased 200,000 Ordinary Shares on 2026-07-31 at $1.7698 per share in a transaction described as a purchase in open market or private transaction, increasing his direct holdings to 500,000 shares. The Rule 10b5-1 trading-plan checkbox was not marked for this transaction.
Aberdeen Group plc and its affiliate abrdn Inc. report beneficial ownership of 8,932,507 Ordinary Shares of ProQR Therapeutics N.V., representing 6.33% of this class of shares. The securities are Ordinary Shares with a nominal value of EUR0.04 per share.
Both Aberdeen Group plc and abrdn Inc. report no sole voting or dispositive power over these shares, but each reports shared voting power and shared dispositive power over 8,932,507 shares. abrdn Inc. beneficially owns the shares on behalf of underlying clients within its corporate group structure.
Eli Lilly and Company reports beneficial ownership of 21,995,880 ordinary shares of ProQR Therapeutics N.V., representing 15.6% of the outstanding class of ordinary shares with a nominal value of 0.04 EUR per share.
Eli Lilly holds sole voting power and sole dispositive power over all 21,995,880 shares and reports no shared voting or dispositive power. The filing is signed by Christopher Anderson, Vice President - Leader of Corporate Securities and Assistant Corporate Secretary.
ProQR Therapeutics N.V. director Bart Filius purchased 150,000 Ordinary Shares on July 17, 2026 at $1.7195 per share in a transaction described as a purchase in the open market or a private transaction. After this trade, he directly holds 300,000 Ordinary Shares of the company.
ProQR Therapeutics N.V. is registering the resale, from time to time, of up to 3,030,303 ordinary shares previously issued to a selling shareholder under an April 7, 2026 Share Purchase Agreement. The company is not selling shares in this offering and will receive no proceeds from any resale.
The shares trade on Nasdaq under “PRQR”; the last reported price was $1.81 per share on July 2, 2026. Ordinary shares outstanding were 105,362,551 as of March 31, 2026 and are expected to be 141,121,476 after including June 2026 equity issuances; this is a baseline figure, not the amount being offered.
ProQR is a clinical-stage biotechnology company developing RNA editing therapies using its Axiomer platform, with lead liver and CNS programs such as AX-0810 for cholestatic diseases and additional collaborations with Lilly and Ginkgo Bioworks. As of March 31, 2026, cash and cash equivalents were €81,088 thousand against total debt of €15,733 thousand.
ProQR Therapeutics N.V. has a shareholder group of Netherlands-based entities and portfolio manager Patrick Johan Hendrik Krol reporting holdings of its ordinary shares on a Schedule 13G/A, based on 141,121,476 ordinary shares outstanding.
Aescap Life Sciences directly holds 4,156,878 shares, or about 2.95% of the class, and Aescap Genetics holds 1,310,271 shares, or 0.93%. Inspirational Visions holds 35,411 shares, or 0.03%. Privium Fund Management B.V., as fund manager of Aescap Life Sciences and Aescap Genetics, may be deemed to beneficially own 5,467,149 shares, or 3.87%.
Through his roles with these entities and a direct holding of 26,302 shares, Krol may be deemed to beneficially own 5,528,862 ProQR shares, or approximately 3.92% of the outstanding ordinary shares. All reporting persons are described as having sole voting and sole dispositive power over their respective positions, with no shared authority reported.
ProQR Therapeutics N.V. Chief Executive Officer Daniel Anton de Boer reported an open-market purchase of 150,000 Ordinary Shares of the company on 9 July 2026 at a price of $1.74 per share. Following this transaction, he directly holds 300,000 Ordinary Shares of ProQR Therapeutics.
ProQR Therapeutics N.V. reported that Chief Executive Officer Daniel Anton de Boer bought Ordinary Shares in the company. On July 7, 2026, he made an open-market purchase of 150,000 Ordinary Shares at $1.59 per share. After this transaction, he directly owns 150,000 Ordinary Shares, indicating this was a new position or a reset position as reflected in this filing.